FINHUB Insights

WST · Q2 FY26 · Jun 30, 2026

West Pharmaceutical Services Q2 FY26: where the revenue came from and where it went

West Pharmaceutical Services Q2 FY26: revenue $0.9B (+14% year over year). Net profit $0.2B. Largest cohort Proprietary Products $0.7B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jun 30, 2026
Reported
Jul 23, 2026 10-Q
Sankey diagram of West Pharmaceutical Services's income statement for Q2 FY26: revenue of $0.9 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$0.9B +14% year over year
Gross profit$0.3B 38% margin
Operating profit$0.2B 21% margin
Net profit$0.2B 18% margin

The numbers

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Jun 30, 2026).
ItemValueShare of revenueYear over year
Revenue 0.9 100% +14%
Proprietary Products 0.7 78% +17%
West Vantage Segment 0.1 11% +2%
Cost of revenue−0.556%
Gross profit0.338% margin+2pp
Research & development−02%+0pp
SG&A−0.213%+1pp
Other−01%+0pp
Operating profit0.221% margin+0pp
Net profit0.218%+0pp
Filing on EDGAR More quarters of WST

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters